Differin 9 dollar settlement over acne treatment alleged false advertising and claims

Differin is an over‑the‑counter acne treatment whose active ingredient, adapalene, was once prescription-only but is now sold widely for acne control. The posted class action settlement covers U.S. purchasers of Differin between January 1, 2020 and February 19, 2026 and offers a $9 payout per class member (no proof of purchase required) with a claims deadline of May 19, 2026. Plaintiffs alleged that marketing and product claims overstated Differin’s benefits or otherwise misled consumers about what the product would deliver, triggering the lawsuit that led to this settlement. The suit was filed to hold the maker accountable for allegedly false or deceptive advertising and to recover purchase losses for consumers; such claims are typically brought under state consumer protection laws and overseen in advertising by the Federal Trade Commission. Because Differin’s active ingredient is regulated as an OTC drug, labeling and claims also have to align with FDA monograph requirements, which adds regulatory context to these disputes. Although a $9 payment is modest, the case fits a broader trend of consumer class actions challenging skincare and cosmetic marketing claims and can spur closer scrutiny of labels, advertising practices, and how companies substantiate “clinically proven” or other efficacy statements.